INTRODUCTION
Acute promyelocytic leukemia (APL) is characterized by a translocation [t (15; 17) ] between the promyelocytic leukemia (PML) and retinoic acid receptor α (RAR α ) genes, generating a PML/RAR α fusion protein that is crucial for a block of myeloid differentiation. 1 APL is the first model of hematological disease treated by differentiation agents. 2 A number of cell lines have been used extensively to study myeloid differentiation and apoptosis, including two human acute promyelocytic leukemia cell lines: NB4, harboring t(15; 17); and HL-60, lacking it. 3 Both cell lines respond to differentiation agents and subsequently die via apoptosis. Exit from the cell cycle is a prerequisite for terminal differentiation, and the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) controls cell cycle progression. 4 Phorbol 12-myristate 13-acetate (PMA) is one of several agents that activate p21 expression under the control of the transcription factor Sp1. 5, 6 In some systems, p21 has been found to protect cells from apoptosis or to promote apoptosis. [5] [6] [7] Another transcription factor, nuclear factor κ B (NF-κ B), which is known as a key regulator of differentiation and cell survival, can exert both proapoptotic and antiapoptotic effects in different cell types. 8 The recognition elements for Sp1 and NF-κ B have been found in the promoter of the FasL gene, which is involved in the Fas/FasL pathway of apoptotic cell death. 9 To date, little is known about the transcription factor regulation of the above-mentioned genes in APL cell maturation and differentiation-associated apoptosis. Here we have examined whether the p21 and FasL genes are controlled by Sp1 and NF-κ B transcription factors during PMA-induced monocytic differentiation and apoptosis of NB4 and HL-60 cells. Our findings demonstrate a capacity of Sp1 and NF-κ B to regulate p21 and FasL promoters positively in monocytic differentiation and negatively in apoptosis of terminally differentiated cells.
MATERIALS AND METHODS

Materials
All chemicals used were of analytical grade and were purchased from Sigma Chemical Co. (St. Louis, MO). Oligonucleotides were synthesized by MWGBiotech AG (Sweden).
Cell Culture
Human acute promyelocytic leukemia HL-60 and NB4 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 µ g/mL streptomycin (Gibco, Grand Island, NY). Cells were grown at 37 ° C in a humidified 5% CO 2 atmosphere and used for assays during the exponential phase of growth.
Evaluation of Cell Differentiation and Apoptosis
Cells were induced to differentiate with 100 nM PMA. At the indicated times, nonadherent cells were collected by gently rocking of the plates. PBS was added back to the culture flasks, and adherent cells were gently scraped from plastic. Monocytic differentiation in the adherent cell population was determined cytochemically using the α -naphthyl acetate esterase kit (Sigma Diagnostics). Cells in the culture supernatant were pelleted at 500 g for 5 min and stained with a 0.01% acridine orange/0.01% ethidium bromide (AO/EtBr) mixture (1:1, v/v) with 6 µ L/100 µ L cell suspension in PBS. 10 Apoptotic cells were evaluated by morphological characteristics using a fluorescence microscope.
Preparation of Nuclear Extracts
Nuclear extracts were prepared from adherent and nonadherent cells. Harvested cells were pelleted at 500 g for 6 min and washed twice in ice-cold PBS. Nuclei were prepared using the Nuclei Isolation Kit (Sigma Chemical Co.) according to the recommendations of the manufacturer. Nuclei were completely suspended in Nuclei EZ storage buffer and frozen at − 76 ° C. Nuclear protein extracts for electrophoretic mobility shift assay (EMSA) were prepared by lysis of nuclei in buffer containing 20 mM Tris-HCl, pH 8.0, 200 mM EDTA, 2 mM EGTA, 20% glycerol, 400 mM NaCl, 1 × protease inhibitor cocktail P2714, 1 mM PMSF, and 3 mM DTT. After incubation for 1 h on ice, the extracts were centrifuged at 18,000 g for 20 min and used immediately. Protein concentrations were measured using a commercial R1C DC Protein Assay (Bio-Rad).
EMSA
Complementary oligonucleotides were annealed and labeled at their 5 ′ ends using [ γ -32 P]ATP (Amersham) and T4 polynucleotide kinase (MBI Fermentas, Inc., Vilnius, Lithuania). Standard DNA-binding reactions were performed with nuclear protein extracts in 20 µ L of reaction buffer (10 mM HEPES, pH 7.9, 80 mM NaCl, 3 mM MgCl 2 , 0.1 mM EDTA, 10% glycerol, and 5 mM DTT), 2 µ g of BSA, 1 µ g of poly(dI-dC), and 1 pmol of labeled oligonucleotide for 30 min at room temperature. When desired, unlabeled competitor oligonucleotide was added to protein extracts at a 50-fold molar excess for a 15-min preincubation. DNA-protein complexes were resolved on 6% polyacrylamide gels containing 1 × Tris-borate-EDTA. After electrophoresis, gels were dried and visualized by autoradiography.
Western Blot Analysis
Cytoplasmic and nuclear protein extracts were isolated from adherent and nonadherent cells using the Nuclei Isolation Kit. The supernatant corresponding to the cytosol fraction was clarified by centrifugation at 20,000 g for 30 min and frozen at − 76 ° C. After determination of protein concentrations using the RC DC Protein Assay, proteins were subjected to Western blot analysis. Twenty micrograms of cytoplasmic or nuclear protein per lane was resolved by 7.5-15% SDS-PAGE and transferred onto Immobilon PVDF transfer membranes. Membranes were blocked with 5% BSA dissolved in PBS containing 0.18% Tween 20 by incubation overnight at 4 ° C. After washing in PBS-Tween 20, filters were probed for 1 h with mouse monoclonal anti-p21 antibody (Santa Cruz Biotechnology) at room temperature, washed four times during 30 min with PBS-Tween 20, and incubated with a 1:2,000 dilution of horseradish peroxidase-conjugated secondary antibody in PBSTween 20 for 1 h at room temperature. The immunoreactive bands were detected with enhanced chemiluminescence (ECL Western blotting detection reagents; Amersham Life Science).
RESULTS
Sp1 Binding Activity to the p21 and FasL Promoters in Differentiated and Apoptotic Leukemic Cells
The p21 promoter contains six binding sites for the transcription factor Sp, which are located near its transcriptional start point. 11 We chose to analyze the p21 promoter region between nucleotides − 135 and − 101. It includes elements 1 and 2 (Sp1-1,2) containing GC-rich motifs. 12 To test the binding of Sp1 to these sites, we performed EMSA using nuclear extracts from NB4 cells treated with 100 nM PMA for 2 h. As shown in F IGURE 1A, three protein complexes were formed, two of which closely resemble the previously observed Sp1 and Sp3, using specific antibodies for these proteins. 12 Protein complexes were designated as Sp1-s (slowly migrating band) and Sp1-f (faster migrating band). We found that the binding of Sp1 and Sp3 proteins to the p21 promoter was efficiently competed by a 50-fold molar excess of unlabeled oligonucleotide (cold). The Sp1-f band is proposed to be Sp1-related pro-FIGURE 1. Sp1-binding activity in differentiated and apoptotic HL-60 and NB4 cells after exposure to PMA. Nuclear extracts from 8-h PMA-treated NB4 cells were used for competition analysis. Oligonucleotides used as probes in EMSA had the following sequences: 5′-GCCTGGGCCCCGGGGGAGGGCGGTCCCGGGCGGCGC-3′ (Sp1 elements 1 and 2 of the p21 promoter) (A), and 5′-ATCAGAAAATTGTGGGCGGAAACTTC CAGG-3′ (Sp1-binding site of the FasL promoter) (B). Sp1 binding was eliminated competitively by the addition of a 50-fold molar excess of self-unlabeled competitor (cold). Arrows indicate DNA complexes with Sp3 and full-length Sp1 (Sp1-s) proteins or with a truncated, faster-migrating form of Sp1 (Sp1-f). Nuclear extracts were prepared from adherent (Dif) and detached, apoptotic (Ap) HL-60 (C) and NB4 (D) cells after treatment with 100 nM PMA for 8 and 48 h. EMSA was performed by using 10 µg of protein from each nuclear extract and oligonucleotide probe containing Sp1 elements 1 and 2 of the p21 promoter or the Sp1-binding site of the FasL promoter. Results are from one representative experiment of two.
tein, being eliminated in the competition assay. Similar protein-DNA complexes were detected using a nucleotide recognition element for Sp1, which is located in the FasL promoter at a position between −296 and −265 bp relative to the transcription start site (FIG.1B) . The upper band represents full-length Sp1, previously recognized by similar electrophoretic mobility and molecular weight. 13 The faster (Sp1-f) band, which was eliminated partially in the competition assay, can likely be attributed to a truncated form or splicing isoform of Sp1. 13 To demonstrate the involvement of Sp1 in differentiation and apoptosis processes, NB4 and HL-60 cells were treated with 100 nM PMA for 8 or 48 h. A small part of the cells became adherent to plastic by 8 h and then underwent morphological differentiation into monocytes after 24-48 h, as determined by α-naphthyl acetate esterase staining. At this time, besides the adherent cells (Dif in FIG. 1C and 1D ), there were detached, apoptotic cells in suspension, as revealed by staining with AO/EtBr (Ap in FIG. 1C and 1D ). As shown in FIGURE 1A and 1D, PMA caused an early response on Sp1 binding to the p21 promoter at 8 h in NB4 cells. Differentiated monocytic cells retained Sp1-binding activity to the p21 and FasL promoters, but it was partially or completely lost in apoptotic cells (48 h; Ap). A very weak Sp1 binding to the p21 promoter was observed in adherent, differentiated HL-60 cells at 48 h, but none to the FasL promoter. A more remarkable loss of Sp1-f complex formation was noted in HL-60 cells undergoing apoptosis, compared with 8-h PMA-treated or mature cells (FIG. 1C) .
Time-Dependent Cytoplasmic p21 Expression during PMA-Stimulated NB4 Cell Differentiation and Apoptosis
Expression of p21 was investigated by Western blot analysis of nuclear and cytoplasmic extracts prepared from adherent and nonadherent PMA-treated NB4 cells. Interestingly, p21 was mainly detected by anti-p21 antibody in the cytoplasmic fraction (FIG. 2) . PMA treatment caused time-dependent changes in the levels of p21 expression. It was undetectable in the cytoplasmic fraction of untreated cells. In the adherent cell population, however, it was significant at 8 h. This finding confirms a previous report that PMA markedly stabilizes the p21 mRNA half-life to 8 h, compared with 1 h in untreated cells. 14 p21 expression increased after 30-72 h of PMA treatment, when monocytic differentiation was evident and the cells became firmly adher- ent. In a mixed cell population of dead and alive cells in suspension, p21 expression was apparent at 24-48 h. In the 72-h cell population, consisting of secondarily detached, apoptotic cells, p21 expression was undetectable. In this regard, monocytic differentiation of NB4 cells was associated with the cytoplasmic expression of p21. A late downregulation of p21 expression was characteristic of apoptotic cells.
NF-B Binding Activity to the p21 and FasL Promoters in Differentiated and Apoptotic Leukemic Cells
To address the role of NF-κB in monocytic differentiation and apoptosis, we analyzed NF-κB binding activity to a consensus NF-κB motif and to the FasL promoter. We used an oligonucleotide corresponding to a putative atypical NF-κB binding sequence in the FasL promoter. It is similar to the site found in the β2-microglobulin promoter. 15 Nuclear extracts from 8-h PMA-treated NB4 cells formed a specific complex with this oligonucleotide probe (FIG. 3A) , as with the probe bearing the consensus NF-κB motif (FIG. 3B) . The binding was eliminated by corresponding unlabeled oligonucleotides. As shown in FIGURE 3C and 3D, PMA stimulated NF-κB binding to a consensus motif in fully differentiated NB4 and HL-60 cells. In contrast, a remarkable loss of NF-κB complex formation was noted in secondarily detached, apoptotic cells. The highest NF-κB binding capacity to the FasL promoter was found FIGURE 3. NF-κB binding activity in differentiated and apoptotic HL-60 and NB4 cells after exposure to PMA. Nuclear extracts from 8-h PMA-treated NB4 cells were used for competition analysis. Oligonucleotides used as probes in EMSA had the following sequences: 5′-AGTTGAGGGGACTTTCCCAGGC-3′ (consensus NF-κB motif) (A), and 5′-AAGCCTGGGCAACATAGAAAGTCCCCATSTGTACAAAAA -3′ (NF-κB binding site of the FasL promoter) (B). NF-κB binding was eliminated competitively by the addition of a 50-fold molar excess of self-unlabeled competitor (cold). Arrows indicate DNA complexes with NF-κB protein. Nuclear extracts were prepared from adherent (Dif) and detached, apoptotic (Ap) HL-60 (C) and NB4 (D) cells after treatment with 100 nM PMA for 8 and 48 h. EMSA was performed by using 10 µg of protein from each nuclear extract and oligonucleotide probe harboring a consensus NF-κB motif or NF-κB binding site of the FasL promoter. Arrows indicate specific protein-DNA complexes. Results are from one representative experiment of two.
in control NB4 cells. It was significantly decreased after PMA stimulation and in mature monocytes (FIG. 3D) . It should be noted that some part of the NB4 cells adhered, but not firmly, after 8 h of PMA treatment. By contrast, HL-60 cells did not adhere at all to plastic at this time, resulting in a similar NF-κB binding capacity as in control cells. The NF-κB binding to the FasL promoter decreased notably in differentiated HL-60 cells and almost disappeared in apoptotic cells (FIG. 3C) . In summary, the NF-κB association to either promoter correlated positively with NB4 and HL-60 cell monocytic differentiation and survival and negatively with apoptosis.
DISCUSSION
It is known that PMA induces cell cycle arrest, differentiation, and apoptosis in many cell types. 16, 17 Here we have demonstrated that PMA-induced NB4 and HL-60 cell monocytic differentiation and apoptosis are associated with changes in Sp1-binding activity to the p21 and FasL promoters. EMSA and Western blotting suggest a requirement for Sp1 in the PMA-induced transcription of p21 in NB4 cells. A significant decrease in Sp1-binding activity to either promoter in apoptotic NB4 cells may be explained by the cleavage of Sp1 during apoptosis and, thereby, a loss of the ability to activate transcription. 18, 19 In HL-60 cells, we observed only a fast-migrating Sp1-f band, the intensity of which decreased in differentiated and apoptotic cells. The absence of Sp1 binding to the p21 and FasL promoters coincides with the presence of a serine protease, myeloblastin, in undifferentiated HL-60 cells. This results in the cleavage of a full-length 105-kDa Sp1 (Sp1-s) protein to a truncated, ∼30-kDa fragment (Sp1-f). 13 The appearance of the Sp1-s band in differentiated HL-60 cells is also parallel with the downregulation of myeloblastin expression during cell differentiation. 19 The cell cycle-inhibitory activity of p21 usually correlates with its nuclear localization and binding to G1 cyclin-cyclin-dependent kinase complexes and proliferating cell nuclear antigen. 4, 20 This allows G1 cell cycle arrest and triggers the early stages of the differentiation program. 21, 22 Expression of p21 in the cytoplasm has been demonstrated in peripheral blood monocytes and U937 cells undergoing monocytic differentiation. 23 Furthermore, relocalization of nuclear p21 to the cytoplasm was found to be associated with resistance to various apoptogenic stimuli. 23 Cytoplasmic p21 forms a complex with the apoptosis signal-regulating kinase 1, proposing another important role for p21 in the protection of cells from apoptosis. 23 FasL induces apoptosis in cells, expressing the Fas receptor upon its cross-linking. 24 HL-60 cells are positive for surface Fas receptor and FasL expression but are resistant to Fas-mediated apoptosis. 25 Still, the role of FasL in the induction of apoptosis remains controversial. Recently, investigation of retinoic acid-treated promyelocytic HL-60 and monoblastic U937 cells revealed a reduction of surface expression of both Fas and its ligand and sensitivity of these cells to anti-Fas-induced apoptosis. 26 We saw changes in FasL gene regulation via the engagement of Sp1 and NF-κB in monocytic differentiation. Moreover, we found a loss of either transcription factor activity in regulating the FasL gene of monocytes that die by apoptosis. Thus, the Fas/FasL pathway is unlikely to play a major role in monocytic differentiationassociated apoptosis.
Since NF-κB binds to a consensus motif in differentiated monocytes but not in apoptotic cells, we suggest that NF-κB is necessary for the survival of mature mono-cytes. This is consistent with previous data showing that NF-κB is persistently activated during PMA-triggered promonocytic cell differentiation. It leads to cell death unless NF-κB is concomitantly activated. 27 This supports a role for NF-κB as an antiapoptotic molecule. 27, 28 Finally, the protective effect of NF-κB might be mediated through p21, since NF-κB induces the expression of p21 during monocyte differentiation to macrophages. 27 This provides a link between NF-κB and p21 and suggests the ability of p21 to cause cell cycle arrest before the induction of differentiation and to protect the monocytes from differentiation-induced cell death.
